Progenitor cell therapy, including but not limited to skeletal myoblasts or hematopoietic cells, is considered investigational as a treatment of damaged myocardium.
Infusion of growth factors (ie, granulocyte colony stimulating factor) is considered investigational as a technique to increase the numbers of circulating hematopoietic cells as treatment of damaged myocardium.